{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:18:17Z","timestamp":1788884297659,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.drugalcdep.2019.107616","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T01:55:19Z","timestamp":1571277319000},"page":"107616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Characteristics and current clinical practices of opioid treatment programs in the United States"],"prefix":"10.1016","volume":"205","author":[{"given":"Christopher M.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony B.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chideha","family":"Ohuoha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinore F.","family":"McCance-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2019.107616_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/00952990.2012.694515","article-title":"Client and program characteristics associated with wait time to substance abuse treatment entry","volume":"39","author":"Andrews","year":"2013","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1360-0443.2011.03637.x","article-title":"Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study","volume":"107","author":"Bukten","year":"2012","journal-title":"Addiction."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ypmed.2018.01.019","article-title":"Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system","volume":"110","author":"Campbell","year":"2018","journal-title":"Prev. Med."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0025","first-page":"11","volume":"14","author":"United States Code of Federal Regulations","year":"2019"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over, 2019 clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jsat.2011.06.005","article-title":"Patterns in admission delays to outpatient methadone treatment in the United States","volume":"41","author":"Gryczynski","year":"2011","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization \u2013 United States, 1999-2014. documented at delivery hospitalization \u2013 United States, 1999-2014","volume":"67","author":"Haight","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0045","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and, 2019 treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0050","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0055","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002209.pub2","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0065","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0070","first-page":"1049","article-title":"Human immunodefciency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up","volume":"6","author":"Metzger","year":"1993","journal-title":"JAIDS."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0075","series-title":"Receipt of Services for Substance Use and Mental Health Issues Among Adults: Results From the 2016 National Survey on Drug Use and Health","author":"Park-Lee","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2018.20851","article-title":"Association among county-level economic factors, clinician supply, metropolitan or rural location, and neonatal abstinence syndrome","volume":"321","author":"Patrick","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0085","series-title":"Substance Use, the Opioid Epidemic, and the Child Welfare System: Key Findings Form a Mixed Methods Study","author":"Radel","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0090","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1377\/hlthaff.2015.1424","article-title":"Hospitalizations related to opioid abuse\/dependence and associated serious infections increased sharply, 2002-12","volume":"35","author":"Ronan","year":"2016","journal-title":"Health Aff."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0095","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/948789","article-title":"Distance traveled and cross-state commuting to opioid treatment programs in the United States","volume":"2011","author":"Rosenblum","year":"2011","journal-title":"J. Environ. Public Health"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0100","series-title":"Despite Infectious Disease Outbreaks Linked to Opioid Crisis, Most Substance Abuse Facilities Don\u2019t Test for HVI or HCV","author":"Sayas","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0105","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths \u2013 United States, 2013-2017","volume":"67","author":"Scholl","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0110","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009","volume":"103","author":"Schwartz","year":"2013","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","article-title":"Access to treatment for opioid dependence in rural America: challenges and future directions","volume":"71","author":"Sigmon","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0120","series-title":"Results From the 2017 National Survey on Drug Use","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0125","series-title":"Treatment Improvement Protocol 63. Medications for Opioid Use Disorder Treatment","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0130","series-title":"Decisions in Recovery: Treatment for Opioid Use Disorder","author":"Substance Abuse and Mental Health Services Administration","year":"2019"},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0135","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users","volume":"174","author":"Tsui","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.15585\/mmwr.mm6709e1","article-title":"Vital signs: trends in emergency department visits for suspected opioid overdose \u2013 united States, July 2016\u2013september 2017","volume":"67","author":"Vivolo-Kantor","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2019.107616_bib0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161930393X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161930393X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:02:10Z","timestamp":1759827730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037687161930393X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":29,"alternative-id":["S037687161930393X"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107616","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and current clinical practices of opioid treatment programs in the United States","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107616"}}